paclitaxel has been researched along with Progeria in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allan, A; Andrés, V; Andrés-Manzano, MJ; Blanco, Y; da Rocha, AM; Díaz-Larrosa, JJ; Fanjul, V; Filgueiras-Rama, D; González-Gómez, C; Gonzalo, P; Jalife, J; Macías, Á; Ponce-Balbuena, D | 1 |
1 other study(ies) available for paclitaxel and Progeria
| Article | Year |
|---|---|
Paclitaxel mitigates structural alterations and cardiac conduction system defects in a mouse model of Hutchinson-Gilford progeria syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cytoskeleton; Disease Models, Animal; Excitation Contraction Coupling; Female; Genetic Predisposition to Disease; Heart Conduction System; Heart Rate; Lamin Type A; Male; Mice, Mutant Strains; Mutation; Myocytes, Cardiac; Paclitaxel; Progeria; Refractory Period, Electrophysiological; Swine; Swine, Miniature; Tubulin | 2022 |